Evaluating the influence of baseline disease characteristics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis in a phase 2 trial

Introduction: BMS-986165 is a potent, highly selective oral tyrosine kinase 2 (TYK2) inhibitor that activates cytokine signaling pathways involved in psoriasis (PsO) pathophysiology. A 12-week, placebo-controlled, Phase 2 trial (NCT02931838) investigated the efficacy and safety of BMS-986165 in patients (pts) with moderate-to-severe plaque PsO. BMS-986165 showed a favorable safety profile, and Psoriasis Area and Severity Index (PASI) 75 responses were the highest at doses ≥3 mg twice daily (BID; 67–75%) vs placebo (7%; P
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research